Viagra works. Cialis works. But a meaningful percentage of men don't respond to PDE5 inhibitors, and others respond but don't like the feel, the headaches, or the partner-dependent mechanism. Peptides target different biology entirely, which is why they sometimes work when the standard drugs don't.
🔑 Key Takeaways
- Peptides for erectile dysfunction work through central-nervous-system arousal pathways (PT-141, Melanotan II, Kisspeptin-10) or vascular and hormonal support (BPC-157, CJC-1295 / Ipamorelin), which is why they can work when Viagra, Cialis, and other PDE5 inhibitors fail
- PT-141 (bremelanotide) is the most evidence-backed option and the only peptide in this category with FDA approval for any sexual dysfunction indication (approved as Vyleesi for female hypoactive sexual desire disorder; used off-label in men)
- Kisspeptin-10 is the newest entrant in this space. It works upstream on the hypothalamic-pituitary-gonadal axis to boost testosterone and sexual motivation, with emerging human trial data
- Melanotan II predates PT-141 by about a decade and produces stronger sexual effects, but carries significant risks (skin darkening, moles, unknown long-term safety) that make PT-141 the preferred melanocortin option for most users
- BPC-157 supports erectile function through vascular and nerve repair mechanisms, which is why some users report improvement after chronic pelvic or lower-spine injuries contribute to ED
- Growth hormone peptides (CJC-1295 / Ipamorelin, Sermorelin, Tesamorelin) indirectly support sexual function via testosterone, body composition, and vitality. They are not first-line ED treatments but round out a full hormonal protocol
- Typical PT-141 dose is 1 to 2 mg subcutaneously 1 to 4 hours before anticipated sexual activity. Most users find a personalized sweet spot through careful titration
- Side effects are manageable: mild nausea, flushing, and transient blood pressure changes are the most common across melanocortin peptides. PT-141 should not be combined with strong antihypertensives without physician supervision
This page covers every peptide with meaningful evidence for erectile dysfunction in 2026: mechanisms, dosing, side effects, head-to-head comparison with PDE5 inhibitors, stacking protocols, and the honest framing of which compounds actually work for which types of ED.
Do Peptides Actually Work for Erectile Dysfunction?
Yes, for specific types of ED and specific mechanisms, with clinical-trial evidence strongest for PT-141.
The medical framing matters here. Erectile dysfunction has three main categories: vascular (blood flow problems, often age or cardiovascular related), neurological / central (brain arousal pathway not firing correctly), and hormonal (low testosterone or disrupted HPG axis). PDE5 inhibitors like Viagra (sildenafil) and Cialis (tadalafil) work on vascular ED by blocking an enzyme that degrades cGMP in penile vascular smooth muscle. When the problem is vascular, they work well.
When the problem is central or hormonal, PDE5 inhibitors often fail because they do not address the actual cause. This is the gap peptides fill. PT-141 activates melanocortin receptors in the brain's sexual arousal pathway. Kisspeptin-10 signals upstream to the hypothalamus to boost natural testosterone and sexual motivation. Melanotan II hits the same melanocortin system as PT-141. BPC-157 helps with neurovascular repair in cases where injury contributes. Each peptide targets a different failure point.
The honest framing: peptides are not a magic bullet for every ED case, but they are genuine tools for the subset of men whose ED stems from non-vascular causes, and they are worth considering when Viagra and Cialis have not delivered the expected result.
The 5 Best Peptides for Erectile Dysfunction: Quick Comparison
| Rank | Peptide | Mechanism | Best for | Evidence |
|---|---|---|---|---|
| #1 | PT-141 (Bremelanotide) | Melanocortin MC3R / MC4R agonist, central arousal | Psychological ED, reduced libido, non-responders to Viagra | FDA-approved as Vyleesi (women), Phase 2 + 3 human trials for men |
| #2 | Kisspeptin-10 | Upstream GnRH stimulation, increases LH / testosterone | Hormonal ED, low testosterone, low sexual motivation | Emerging human clinical trials, Imperial College London research |
| #3 | Melanotan II | Broad melanocortin agonist (MC1R-MC5R) | Strong sexual arousal response | Historical precursor to PT-141, carries skin pigmentation and mole risks |
| #4 | BPC-157 | Angiogenesis, nerve repair, growth factor signaling | Injury-related ED, pelvic trauma recovery | Strong animal data, emerging human clinical use |
| #5 | CJC-1295 + Ipamorelin | GH secretagogue, indirect testosterone support | Age-related decline, body composition, libido | Established GH peptide data, indirect ED evidence |
How Peptides Treat ED Differently Than Viagra
PDE5 inhibitors (Viagra, Cialis, Levitra, Stendra) block the enzyme that breaks down cGMP in the penile vascular smooth muscle. More cGMP means more vasodilation, which means more blood flow when sexual stimulation initiates the process. The key word is "when." PDE5 inhibitors do not create arousal. They amplify the vascular response to arousal that already exists.
Peptides work earlier in the signaling cascade. PT-141 and Melanotan II activate melanocortin receptors in the brain, which triggers the neurological arousal state that normally drives vascular response. Kisspeptin-10 works further upstream still, at the hypothalamic level, influencing the hormonal environment that primes the brain to respond to sexual cues. BPC-157 operates on the physical tissue and nerve level, useful when damage is the bottleneck.
For men whose ED has a vascular root cause and who respond well to Viagra, PDE5 inhibitors remain the first-line treatment. For men whose ED has psychological, central, hormonal, or neurological components, peptides address the actual failure point rather than amplifying a vascular response to a signal that is not coming.
Quick Mechanism Answer
- Viagra / Cialis: Vascular, requires existing arousal to amplify
- PT-141: Central nervous system arousal trigger, works independent of stimulation
- Kisspeptin-10: Upstream hormonal, increases sexual motivation and testosterone
- Melanotan II: Broader melanocortin agonism, stronger but riskier
- BPC-157: Repair mechanism, relevant when injury contributes to ED
- CJC-1295 / Ipamorelin: Indirect GH / testosterone boost, supports overall vitality
#1: PT-141 (Bremelanotide), The Most Effective Option
PT-141 is the standout peptide in this category. Sold as Vyleesi in the US for female hypoactive sexual desire disorder, it has the most strong clinical trial dataset of any peptide targeting sexual function. It is used off-label in men at the same or lower doses.
Central Arousal Activation
PT-141 binds melanocortin receptors MC3R and MC4R in the hypothalamus. Activating these receptors triggers the neurological cascade that produces sexual arousal, independent of visual or tactile input. This is a fundamentally different mechanism from every PDE5 inhibitor on the market and it is the reason PT-141 can work when Viagra cannot.
Works Without Stimulation
A unique property of PT-141 is that the arousal response initiates centrally. Most users describe spontaneous arousal within 1 to 4 hours after subcutaneous injection, often in situations where external stimulation has not occurred. This is a meaningful practical advantage for men whose ED has a central rather than vascular origin.
1 to 4 Hour Onset Window
Onset is slower than Viagra (30 to 60 minutes) but the effect window is longer for most users. Peak activity typically lands 2 to 3 hours post-injection. Some users report effects lasting into the next day at higher doses, though the peak intensity declines after the initial window.
Stacks Well
PT-141 can be layered with PDE5 inhibitors when vascular response is also limited. Central arousal (PT-141) plus vascular amplification (Viagra or Cialis) covers both mechanisms. Many physicians running off-label ED protocols combine the two at reduced doses of each.
#2: Kisspeptin-10, The Upstream Hormonal Approach
Kisspeptin-10 is the newer entrant in the peptide ED space. It works upstream of everything else on this list by signaling the hypothalamus to release more gonadotropin-releasing hormone (GnRH), which in turn stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH), ultimately raising testosterone.
Research at Imperial College London (Dhillo lab) has produced the most compelling human trial data for Kisspeptin in sexual function. Studies have shown Kisspeptin administration increases neural activity in brain regions associated with sexual arousal, improves subjective sexual motivation, and raises testosterone levels in a physiological (rather than supraphysiological) pattern.
Kisspeptin shines when the underlying ED cause is hormonal: low testosterone, low sexual motivation even when physical erection is possible, or age-related decline in sexual drive. It is less useful for purely vascular or mechanical ED.
Typical community protocols use 100 to 500 mcg subcutaneously daily or every other day, cycled 4 to 8 weeks. For the full mechanism breakdown see our Kisspeptin peptide guide.
#3: Melanotan II, Strong but Risky
Melanotan II (MT-II) predates PT-141 by about a decade and was the peptide that originally revealed the connection between melanocortin receptor activation and sexual arousal. The tanning-related sexual side effects observed in MT-II research are what eventually led to the development of PT-141 as a cleaner sexual-function-specific variant.
MT-II is a broader melanocortin agonist, hitting MC1R through MC5R. The MC1R activation produces skin darkening (the "tanning peptide" reputation). The MC3R and MC4R activation produces sexual arousal, similar to PT-141. The broader receptor profile produces stronger subjective sexual effects than PT-141 for many users.
Melanotan II Risks to Know
- Skin darkening: Expected effect, but can be uneven or unpredictable
- New moles or darkening of existing moles: Requires dermatology monitoring
- Melanoma risk (theoretical): Increased melanocyte activation raises concern, though no causal link has been confirmed
- Unknown long-term safety: Never completed clinical development
- Nausea and flushing: Stronger than PT-141 due to the broader receptor activation
- Priapism: Prolonged erection is possible at higher doses. Medical emergency if it lasts more than 4 hours
For most users seeking a melanocortin-pathway peptide for ED, PT-141 is the cleaner option. Melanotan II is still on the menu for users who do not respond adequately to PT-141 and accept the additional risk profile. See our Melanotan dosage guide for the full breakdown.
#4: BPC-157, The Vascular and Repair Angle
BPC-157 is not a direct ED treatment. It becomes relevant in a specific subset of cases: ED that emerges after pelvic surgery, cycling injury, lower-back nerve damage, or chronic pelvic floor dysfunction. In these scenarios, the root cause is physical, and a compound that supports tissue repair and angiogenesis can address the underlying problem.
Animal data on BPC-157 shows strong angiogenic activity (new blood vessel formation), nerve repair support, and broad soft-tissue recovery effects. Human data is more limited but emerging, and the community use pattern reports consistent improvement in injury-related ED contexts.
Typical protocols use 250 to 500 mcg subcutaneously daily for 4 to 6 weeks, cycled. The effect on ED specifically is gradual rather than acute, which makes BPC-157 an adjunct rather than a primary tool. For the full BPC-157 profile see our BPC-157 page.
#5: Growth Hormone Peptides (CJC-1295 + Ipamorelin)
The growth hormone secretagogue stack (CJC-1295 + Ipamorelin or CJC-1295 + Sermorelin) supports sexual function indirectly through several mechanisms:
- Testosterone support: Healthy GH levels correlate with healthy testosterone production. Men with age-related GH decline often have coincident testosterone decline
- Body composition: Lower body fat and higher lean mass improve insulin sensitivity, which reduces the vascular component of ED risk
- Vitality and energy: GH optimization broadly improves the subjective sense of vigor that underlies sexual drive
- Sleep quality: GH peaks during deep sleep, and better sleep improves testosterone production
For men with age-related decline as the root cause of their ED, the GH peptide stack is a reasonable long-term protocol. It will not deliver the acute effect of PT-141, but it addresses foundational vitality over 3 to 6 months. See our CJC-1295 guide and Ipamorelin guide for full details.
PT-141 vs Sildenafil: Head-to-Head
| PT-141 (Bremelanotide) | Sildenafil (Viagra) | |
|---|---|---|
| Mechanism | Central: melanocortin arousal pathway | Vascular: PDE5 inhibition |
| Administration | Subcutaneous injection | Oral tablet |
| Onset | 1 to 4 hours | 30 to 60 minutes |
| Duration of effect | 6 to 10 hours at peak | 4 to 6 hours |
| Requires stimulation? | No, creates arousal independently | Yes, amplifies existing arousal |
| Libido effect | Increases subjective desire | No direct effect on desire |
| Psychological ED | Often effective | Often ineffective |
| Typical side effects | Nausea, flushing, transient BP rise | Headache, flushing, nasal congestion |
| Cost per dose | ~$3 to $8 (compounded) to $100+ (Vyleesi) | ~$1 to $4 (generic) to $70 (brand) |
Peptide ED Dosage Chart
| Peptide | Typical Dose | Route | Timing | Cycle |
|---|---|---|---|---|
| PT-141 | 1 to 2 mg | Subcutaneous | 1 to 4 hours before activity | As needed, no more than twice weekly |
| Kisspeptin-10 | 100 to 500 mcg | Subcutaneous | Morning, daily or every other day | 4 to 8 weeks on, 2 to 4 weeks off |
| Melanotan II | 0.25 to 0.5 mg (loading), 0.5 to 1 mg (arousal) | Subcutaneous | Loading phase before arousal use | Loading 2 to 3 weeks, then as needed |
| BPC-157 | 250 to 500 mcg | Subcutaneous | Morning or evening, daily | 4 to 6 weeks on, 2 to 4 weeks off |
| CJC-1295 + Ipamorelin | 100 mcg each (daily), or 200/200 mcg (3x weekly) | Subcutaneous | Evening, 2 to 3 hours after eating | 12 weeks on, 4 weeks off |
All dosing is community-derived except for PT-141, where FDA Vyleesi dosing (1.75 mg prefilled auto-injector for women) provides a clinical reference point. Men often use 1 to 2 mg based on individual response. Most users find their personal sweet spot through careful titration, starting low and adjusting over 2 to 4 sessions.
Best Peptide Stacks for Erectile Dysfunction
Stack 1: PT-141 + Kisspeptin-10 (Central + Hormonal)
For ED with both psychological and hormonal components. Kisspeptin-10 runs as a daily background protocol to optimize testosterone and sexual motivation. PT-141 is used acutely as needed for specific sexual encounters. This stack addresses the underlying hormonal environment while providing an on-demand acute arousal tool.
Stack 2: PT-141 + Low-Dose Sildenafil (Central + Vascular)
For ED with mixed central and vascular causes. Reduced doses of each are often used together, with PT-141 providing the central arousal and sildenafil amplifying the vascular response. Physician supervision is important because both can affect blood pressure.
Stack 3: CJC-1295 + Ipamorelin + BPC-157 (Long-Term Vitality)
For men focused on foundational improvement over 3 to 6 months rather than acute effect. Growth hormone optimization plus BPC-157 tissue repair addresses the body composition, cardiovascular health, and physical recovery components that underlie long-term sexual function. Not an acute tool, but a solid long-term protocol.
Stack 4: PT-141 + BPC-157 (Arousal + Recovery)
For men recovering from pelvic surgery, prostatectomy, cycling injury, or similar physical trauma. PT-141 provides central arousal while BPC-157 supports the tissue and nerve repair that underlies the physical substrate. This is particularly common in post-prostatectomy ED protocols.
Who Should Consider Peptides for ED?
- Non-responders to PDE5 inhibitors: If Viagra, Cialis, Levitra, and Stendra have all failed to produce adequate response, peptides target different biology and may succeed where they failed
- Psychological or central ED: When the physical plumbing is fine but arousal is not firing, PT-141 or Kisspeptin-10 address the actual failure point
- Low libido with or without ED: PT-141 and Kisspeptin-10 both address libido, which PDE5 inhibitors do not
- Post-prostatectomy: BPC-157 plus PT-141 protocol is commonly used in men recovering from prostate surgery
- Age-related vitality decline: GH peptide stack plus Kisspeptin-10 for foundational hormonal support
- Young men with persistent ED despite no obvious medical cause: Often a good fit for PT-141 because the underlying cause is frequently central or psychological
- Men uncomfortable with PDE5 inhibitor side effects: Headaches, flushing, nasal congestion, back pain, and visual disturbances can make Viagra and Cialis unwelcome
Psychological ED: Where PT-141 Really Shines
A significant percentage of men with ED have no identifiable physical cause. Cardiovascular workup is clean, testosterone is normal, there is no neurological damage, and yet erections are inconsistent or fail at critical moments. This is psychological ED, and it is where PT-141 demonstrates its biggest relative advantage over PDE5 inhibitors.
The clinical logic: psychological ED means the brain's arousal signal is compromised (anxiety, performance pressure, relationship stress, depression, or simply a mismatch between expected and actual arousal). PDE5 inhibitors cannot fix this because they amplify a vascular response to a signal that is not coming. PT-141 triggers the signal directly at the central nervous system level, which can cut through performance anxiety in a way oral ED drugs cannot.
Many men report that PT-141 restores not just physical function but the subjective sense of sexual anticipation that had faded. This is a qualitatively different outcome than Viagra produces, and it is why men with psychological ED often strongly prefer PT-141 once they have tried both.
PT-141 and Hormonal ED: Setting Realistic Expectations
Before starting PT-141 or any peptide for ED, check your hormonal baseline. Low testosterone is a common root cause of ED and sexual dysfunction, and no peptide works as well as simply correcting low testosterone in patients who have it.
The standard workup:
- Total testosterone (morning draw, fasted)
- Free testosterone
- LH and FSH
- Prolactin
- Estradiol
- SHBG
- TSH, Free T3, Free T4 (thyroid)
- Fasting glucose and HbA1c
- Lipid panel
If total testosterone is below 300 ng/dL or free testosterone is low, addressing that hormonal deficit through TRT, clomiphene, enclomiphene, HCG, or Kisspeptin-10 will typically produce more durable improvement than PT-141 alone. PT-141 can still be a useful adjunct for acute arousal, but it is not a substitute for correcting an underlying hormonal deficit.
Side Effects
| Side effect | Peptide | Frequency | Notes |
|---|---|---|---|
| Nausea | PT-141, Melanotan II | Common (~40% at higher doses) | Melanocortin receptor side effect, reduces with dose adjustment |
| Flushing | PT-141, Melanotan II | Common | Warmth sensation, typically 30 min to 2 hours post-dose |
| Transient blood pressure rise | PT-141 | Variable | Usually mild, monitor if on antihypertensives |
| Darkening of skin or moles | Melanotan II | Expected | MC1R activation. Requires dermatology monitoring |
| Prolonged erection (priapism) | PT-141, Melanotan II | Uncommon | Medical emergency if over 4 hours |
| Injection site reaction | All injectable peptides | Occasional | Rotate injection sites |
| Mild headache | All peptides occasionally | Uncommon | Hydration usually resolves |
| Mild GH side effects (water retention) | CJC-1295, Ipamorelin | Occasional | Resolves with continued use or dose reduction |
Safety Monitoring
For men starting a peptide protocol for ED, baseline and follow-up labs are prudent practice.
Baseline Labs
- Total and free testosterone, SHBG
- LH, FSH, prolactin, estradiol
- TSH, Free T3, Free T4
- Full metabolic panel (CMP)
- Lipid panel
- Fasting glucose and HbA1c
- Blood pressure (baseline)
- Dermatology exam (if considering Melanotan II)
Recheck Intervals
- Hormonal panel every 3 to 6 months during a GH peptide or Kisspeptin protocol
- Blood pressure at every prescriber visit
- Dermatology every 6 months if on Melanotan II
- Re-check testosterone and LH after 8 weeks of Kisspeptin-10
Who Should Not Use Peptides for ED
Do Not Use If You:
- Have uncontrolled hypertension or severe cardiovascular disease (PT-141 and Melanotan II can transiently raise blood pressure)
- Have prostate cancer or other androgen-sensitive malignancy (Kisspeptin-10 increases testosterone)
- Have a history of melanoma or multiple atypical moles (Melanotan II contraindicated)
- Take MAOIs (theoretical interaction risk with melanocortin peptides)
- Are under 18 (no pediatric data for any of these peptides in this indication)
- Have known hypersensitivity to the peptide or any component
Where to Buy Peptides for ED
Source quality matters. In the US, Vyleesi (PT-141) is FDA-approved and available by prescription for women, with some physicians prescribing off-label for men. For compounded or lab-grade options, look for:
- ≥98% purity verified by HPLC and mass spectrometry
- Third-party Certificate of Analysis (COA) per batch
- US-based manufacturing with cold-chain handling
- Lyophilized vials (typically 10 mg for PT-141, Kisspeptin-10, and Melanotan II)
- Clear batch numbers and lot documentation
Avoid any source that cannot provide independent lab verification. For a full vendor walkthrough, see our best legit peptide vendors guide.
Frequently Asked Questions
References
- Kingsberg, S. A., et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstetrics & Gynecology, 134(5), 899-908.
- Clayton, A. H., et al. (2020). Bremelanotide: A Melanocortin Receptor Agonist for Premenopausal Women With HSDD. Women's Health.
- Safarinejad, M. R., & Hosseini, S. Y. (2008). Salvage of sildenafil failures with bremelanotide: A randomized, double-blind, placebo controlled study. Journal of Urology, 179(3), 1066-1071.
- Rosen, R. C., et al. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141 in healthy male subjects. International Journal of Impotence Research.
- Dhillo, W. S., et al. (2005). Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology & Metabolism, 90(12), 6609-6615.
- Thurston, L., et al. (2021). Melanocortin MT1 and Kisspeptin Mechanisms in Human Sexual Arousal. JAMA Network Open.
- Abbara, A., et al. (2023). Kisspeptin receptor agonist has therapeutic potential in hypoactive sexual desire disorder. JCI Insight.
- Sikiric, P., et al. (2018). BPC-157 as a potential treatment for cardiovascular conditions. Current Pharmaceutical Design.
- Safarinejad, M. R. (2008). Evaluation of the safety and efficacy of bremelanotide in treating erectile dysfunction. European Urology.
- Pfaus, J. G., et al. (2007). Selective facilitation of sexual solicitation in female animals by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences, 104(25), 10201-10204.
- FDA. (2019). FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. US Food and Drug Administration.
- Diamond, L. E., et al. (2004). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide, a melanocortin receptor agonist. Journal of Sexual Medicine, 1(Suppl 1), S18.
